Marc S. Raab, MD, PhD, details how agents such as carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
Marc S. Raab, MD, PhD
Advertisement
Articles by Marc S. Raab, MD, PhD
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
Advertisement
Latest Updated Articles
Considering Subsequent Treatment in NDMM After Teclistamab-Based InductionPublished: September 23rd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Advises Against BLA for Novel Vaccine Combo/Pembrolizumab in Melanoma
2
Moving Beyond Chemotherapy in Relapsed/Refractory ES-SCLC Treatment
3
Anito-cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma
4
Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC
5
